SGSimone de Vasconcelos Generoso

Simone de Vasconcelos Generoso

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Simone de Vasconcelos Generoso has a total of 154 co-authors. Here are the top co-authors by number of shared publications:

  • Geovanni Dantas Cassali

    Department of General Pathology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

    5 shared publications
  • Luísa Martins Trindade

    Graduate Program in Food Science, Federal University of Minas Gerais, Belo Horizonte, Brazil

    5 shared publications
  • Maria Isabel Toulson Davisson Correia

    Department of Surgery, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

    5 shared publications
  • Valbert Nascimento Cardoso

    Federal University of Minas Gerais, School of Pharmacy, Department of Food Science, Pampulha, Belo Horizonte, Minas Gerais, Brazil

    5 shared publications
  • Flaviano dos Santos Martins

    Graduate Program in Microbiology, Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

    4 shared publications
  • Amanda Dias Borges

    Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

    3 shared publications

Latest Publications

  • Open Access

    Curcumin and Tamoxifen in Breast Cancer Therapy: A Scoping review

    by Eunice da Silva Barros, Marcelo Victor Teixeira da Silva, Samanta Thomas Valdés, Bruna Teles Soares Beserra, Simone de Vasconcelos Generoso

    Tamoxifen (TMX) is a widely used first-line hormonal therapy for breast cancer; however, prolonged use is associated with hepatic toxicity and endocrine resistance, potentially compromising treatment outcomes. Curcumin (CUR) has been investigated as a potential adjuvant to TMX therapy. This scoping review aimed to map the existing scientific evidence on the effects of CUR co-administration with TMX in breast cancer treatment. The review followed PRISMA-ScR guidelines and searched six databases (PubMed, Scopus, Web of Science, Embase, Cochrane Library, and Google Scholar) for studies published between 2005 and 2025. In vitro, in vivo, and clinical studies evaluating CUR and TMX co-administration were included. Of 1,343 records identified, 14 studies met the inclusion criteria: 11 in vitro, two clinical trials, and one combined in vivo/in vitro study. Most preclinical studies reported synergistic effects under experimental conditions. Although several preclinical studies reported synergistic effects under experimental conditions, the available clinical evidence remains limited and inconsistent.

  • Open Access

    Perceptions of nutritional care and the role of dietitians in oncology: a cross-sectional study of healthcare professionals and patients

    by Marcelo Victor Teixeira da Silva, Isabela Diniz Aguiar, Eunice da Silva Barros, Ana Luiza Moraes dos Santos, Maria Isabel Toulson Davisson Correia, Silvia Fernandes Mauricio, Simone de Vasconcelos Generoso

  • Open Access

    Assessment of Translocation of Lacticaseibacillus rhamnosus CGMCC 1.3724 Radiolabeled with Technetium-99 m Isotope in an Experimental Model of Immunosuppression

    by Nayara Salgado Vieira Sette, Maria Emília Rabelo Andrade, Luísa Martins Trindade, Amanda Dias Borges, Carla Carolina Martins Carneiro, Bárbara Gatti Cardoso, Simone Odília Antunes Fernandes, Bruno Galloti, Flaviano dos Santos Martins, Paola Caroline Lacerda Leocádio, et al.

    A: Immunosuppressant medications disrupt intestinal homeostasis. Probiotics may help restore intestinal balance; however, the safety of their use in immunocompromised individuals is questionable. To investigate the translocation of Lacticaseibacillus rhamnosus radiolabeled with technetium-99m ( 99m Tc) in an experimental model of immunosuppression. Mice were divided into four groups: control (CTL), 5-fluorouracil (5-FU), dexamethasone (DEX), and DEX + 5-FU. Mice in the CTL group received saline (0.1 mL/intraperitoneal [IP]) for seven days; those in the 5-FU group received a single dose of 5-fluorouracil (300 mg/kg/IP) on day 5; those in the DEX group received dexamethasone (5 mg/kg/IP) daily; and those in the DEX + 5-FU group received a single dose of 5-fluorouracil (300 mg/kg/IP) on day 5 and dexamethasone (5 mg/kg/IP) daily. On day 8, the animals received radiolabeled L. rhamnosus (99mTc-L. rhamnosus ) by oral gavage. Four hours later, the mice were anesthetized and euthanized for blood and tissue collection. The 5-FU group exhibited leukopenia, whereas the DEX and DEX + 5-FU groups showed granulocytosis and lymphopenia. Radiolabeling demonstrated high stability. Significant probiotic translocation occurred in the 5-FU group, whereas no translocation was observed in the DEXgroup. Intermediate levels of translocation were detected in the DEX + 5-FU group. As expected, 5-FU treatment induced pronounced epithelialinjury, characterized by increased intestinal permeability, oxidative stress, histological damage, and inflammatory infiltration. In the DEX + 5-FUgroup, although histological and morphometric alterations were similar to those observed in the 5-FU group, and peroxidase activity wasincreased with an intermediate reduction in superoxide dismutase levels, intestinal permeability remained unchanged.

  • Preoperative symbiotic supplementation modulates the intestinal microbiota of patients with colorectal cancer: Evidence from a randomized clinical trial

    by Luísa Martins Trindade, Amanda Dias Borges, Rodrigo Dias de Oliveira Carvalho, Bianca Fernandes Gomes, Mariana Teixeira da Silva, Nayara Salgado Vieira Sette, Luiza Rogério, Gregório Grama Cavalcanti, Ana Paula Vargas Garcia, Geovanni Dantas Cassali, et al.


  • Open Access

    Vitamin C and L-arginine as potential synergistic adjuvants to recover intestinal mucositis induced by chemotherapy

    by Amanda Dias Borges, Raquel Baumgratz Marques, Luiz Octávio Pires, Luísa Martins Trindade, Nayara Salgado Vieira Sette, Maria Emília Rabelo Andrade, Samanta Thomas-Valdés, Paola Caroline Lacerda Leocádio, Jacqueline Isaura Alvarez-Leite, Fernanda Rezende Souza, et al.

  • Mitigation of chemotherapy-induced experimental intestinal mucositis through postbiotic lactate

    by Isabel David Matos, Amanda Dias Borges, Luísa Martins Trindade, Maria Emília Rabelo Andrade, Gregório Grama Cavalcante, Paola Caroline Lacerda Leocádio, Jacqueline Isaura Alvarez-Leite, Geovanni Dantas Cassali, Bruno Galotti Costa, Flaviano dos Santos Martins, et al.

    Postbiotic lactate modulates the immune system in inflammatory bowel diseases. However, its role in experimental intestinal mucositis (IM) has not been elucidated. This study aimed to evaluate the effects of lactate supplementation (1 and 2 × 10−1 mol/L) in a 5-fluorouracil (5-FU)-induced IM model. Male BALB/c mice (6–8 weeks old) were randomly divided into four groups: control (CTL), mucositis (MUC), mucositis with 1 × 10−1 mol/L lactate solution (MUC10), and mucositis with 2 × 10−1 mol/L lactate solution (MUC200). Lactate was administered via oral gavage for 10 days. Following the treatment period, the animals were subjected to an intraperitoneal injection of 300 mg/kg 5-FU to induce IM and were euthanized 72 h later for analysis. The MUC group presented intestinal damage with a poor histological score and decreased morphometric parameters as well as decreased mucus production and increased inflammatory infiltration and intestinal permeability compared to those of the CTL group (p < 0.05). However, the MUC200 group exhibited better results for the evaluated parameters than the MUC group (p < 0.05). Notably, the results in the MUC10 group were similar to those in the MUC group (p > 0.05). In conclusion, lactate supplementation attenuates mucositis-induced damage in a dose-dependent manner.


  • Open Access

    Association between KRAS mutation and alcohol consumption in Brazilian patients with colorectal cancer

    by Bianca Gomes-Fernandes, Luísa Martins Trindade, Marcela de Castro Bastos Rodrigues, João Pedro Duarte Cardoso, Frederico Temponi Lima, Luíza Rogerio, Simone de Vasconcelos Generoso, Juliana Garcia Carneiro, Rodrigo Gomes da Silva, Renan Pedra de Souza, et al.

    Colorectal cancer (CRC) is a leading cause of morbidity and mortality worldwide. Detection before metastasis and efficient treatment of disease significantly improve patient survival and quality of life. However, limitations in diagnosis and postoperative surveillance are associated with low CRC detection and survival rates. Thus, this project aimed to evaluate the molecular profile of patients diagnosed with CRC, as molecular biomarkers constitute a new frontier for diagnosis, treatment and prognosis. Methods and Results: 42 patients were included in the study, predominantly male (59.5%), with a median age of 63 years (SD: 10.0; min: 41; max: 83). The majority of primary tumors were located in the rectum (38.1%), in the sigmoid (33.3%) and in the ascending (21.4%) colon. We evaluated the genes KRAS, NRAS, BRAF, EGFR and TP53 using Sanger sequencing. Somatic and germline mutations were found in the KRAS, EGFR and TP53 genes, with the most common somatic alteration being rs121913529 in KRAS. This variant was also strongly associated with alcoholism (p = 0.002). Furthermore, patients with somatic mutations in TP53 had significantly higher mortality compared to those with wild-type alleles (OR: 11.2; 95% CI 1.25–2.45). Conclusions: Our findings support a relationship between alcohol consumption and the rs121913529 mutation, which is classified as pathogenic for colorectal cancer. Thus, further studies investigating the link between alcohol consumption, colorectal carcinogenesis and tumor progression ought to be conducted.


  • Association between nutrition intake and muscle mass in adult inpatients receiving nutrition support: A prospective cohort study

    by Luciana de Abreu Silva, Simone de Vasconcelos Generoso, Vanessa Moreira da Rocha, Lincoln Antinossi Cordeiro da Mata, Carolina Fernandes Castro, Mariana Vassallo Ribeiro, Bruna Guerra Campolina, Camila Kümmel Duarte

    Objective: The present study aimed to evaluate the association between muscle mass variation, estimated by different equations, during hospitalization with the energy and protein intake and clinical and nutrition outcomes of patients using nutrition support.Methods: A prospective observational study with patients older than 18 years in use of enteral and/or parenteral nutrition therapy and monitored by the Nutritional Therapy Committee between December 14, 2021, and December 14, 2022. Data were collected from the electronic records and were applied in 11 equations to estimate the four different portions of muscle mass of patients receiving nutrition support at the beginning and the end of hospitalization.Results: A total of 261 patients were evaluated, with a median age of 61.0 (49.0–69.75) years, and 106 were women (40.6%). According to the nutrition diagnosis, several participants had severe malnutrition (39.5%). The most muscle mass estimation equations indicated a reduction of muscle mass during hospitalization. All patients presented negative energy and protein balances during hospitalization, but greater protein intake increased the lean soft tissue. Also, the greater the number of infections, metabolic complications, and scheduled diet interruption, the greater was the chance of losing muscle mass.Conclusion: There can be an association between the variation in muscle mass and energy and protein intake during hospitalization of patients using nutrition support. In addition, variation in muscle mass was associated with complications from nutrition support. The results emphasize the importance of anthropometric measurements to estimate muscle mass when other methods are not available.


  • Comparison of pre- and posttransplant energy expenditure in patients undergoing hematopoietic stem cell transplantation and evaluation of associated factors

    by Izabella Barbosa Vieira, Nayara Salgado Vieira Sette, Cristiane Alves de Oliveira, Maria Isabel Toulson Davisson Correia, Camila Kummel Duarte, Simone Vasconcelos Generoso


  • Acute intake of fructooligosaccharide and partially hydrolyzed guar gum on gastrointestinal transit: A randomized crossover clinical trial

    by Marcelo Victor Teixeira da Silva, Shirleide Santos Nunes, Walyson Coelho Costa, Sandra Monetti Dumont Sanches, Ana Letícia Malheiros Silveira, Álida Rosária Silva Ferreira, Roberta Silva Filha, Maria Isabel T.D. Correia, Luciene das Graças Mota, Simone de Vasconcelos Generoso